# A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

> **NCT05306340** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 373 (actual)

## Conditions studied

- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Giredestrant
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant
- **DRUG:** Tamoxifen
- **DRUG:** Everolimus
- **DRUG:** LHRH Agonist
- **DRUG:** Dexamethasone Mouth Rinse

## Key facts

- **NCT ID:** NCT05306340
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-03
- **Primary completion:** 2025-07-16
- **Final completion:** 2026-10-15
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05306340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05306340, "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05306340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*